



## HOUSE COMMITTEE ON WAYS & MEANS CHAIRMAN RICHARD E. NEAL

### KEY DRUG PRICING FACTS FOR CA-10 (Rep. Josh Harder) *Know Your District*

In CA-10, there are **92,196 people enrolled in a Medicare Part D plan** and **469,577 people enrolled in private health insurance** – all of whom stand to benefit from the passage of *H.R. 3 The Lower Drug Costs Now Act*.

Source of Prescription Drug Coverage	CA-10 Residents	
Medicare Prescription Drug Plan (PDP)	5.5%	(41,861 People)
Medicare Advantage Prescription Drug (MA-PD)	6.6%	(50,297 People)
Medicare Part D (Any Plan)	12.2%	(92,196 People)
Private Health Insurance	61.9%	(469,577 People)

Source: Committee tabulations of U.S. Census Bureau, 2017 American Community Survey 1-year estimates

Note: Some insurance categories include people who have multiple sources of coverage. Some insurance categories are not included. Therefore, totals will not sum up to 100%.

## Cancer Medications

There are an estimated **15 million Americans living with cancer**, including **186,920 annual cancer diagnoses in California**. In 2019, an estimated **60,590 California residents will die of cancer**. Most cancer medications cost patients **over \$100,000 annually** in the U.S., which is why 90 percent of Americans say cancer drugs are too expensive.

### *BREAST CANCER*

In 2019, an estimated **27,700 women in California will be diagnosed with breast cancer**.

H.R. 3 can lower the average total cost of the breast cancer medication Ibrance by 65% from **\$69,000 to \$23,900 per year**.

Source: Committee tabulations of American Cancer Society, 2019 Cancer Statistics Center, and 2018 pharmaceutical price data from recognized price sources.

### *LEUKEMIA*

In 2019, an estimated **6,030 people in California will be diagnosed with leukemia**.

H.R. 3 can lower the average total cost of the leukemia medication Tasigna by 71% from **\$93,700 to \$27,400 per year**.

Source: Committee tabulations of American Cancer Society, 2019 Cancer Statistics Center, and 2018 pharmaceutical price data from recognized price sources.

### *PROSTATE CANCER*

In 2019, an estimated **24,550 people in California will be diagnosed with prostate cancer**.

H.R. 3 can lower the average total cost of the prostate cancer medication Zytiga by 66% from **\$109,500 to \$37,400 per year**.

Source: Committee tabulations of American Cancer Society, 2019 Cancer Statistics Center, and 2018 pharmaceutical price data from recognized price sources.



## *H.R. 3 will Reduce Drug Costs for Millions of Americans*

### *ARTHRITIS*

18.3% of California residents have arthritis, 29.3% of whom experience severe joint pain because of it. H.R. 3 can lower their total costs on most arthritis drugs from about **\$40,000 to \$10,000 per year**.

Source: Arthritis Foundation, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

### *ASTHMA*

About 7.9% or 2,398,304 California residents live with asthma. H.R. 3 can lower their total costs on most asthma drugs from about **\$1,400 to \$270 per year**.

Source: Centers for Disease Control and Prevention, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

### *HIV/AIDS*

In 2015, 4,495 California residents were diagnosed with HIV. H.R. 3 can lower their total costs on most HIV drugs from about **\$15,000 to \$6,000 per year**.

Source: Centers for Disease Control and Prevention, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

### *MULTIPLE SCLEROSIS*

One million people are living with Multiple Sclerosis (MS) in the United States. H.R. 3 can lower their total costs on most MS drugs from about **\$40,000 to \$13,000 per year**.

Source: MS Society, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

## **Insulin**

**30.3 million Americans** live with diabetes, including **3,088,741 people in California**. Over the past decade, the price of insulin has **increased 197 percent**, and Medicare Part D spending on insulin has **increased 840 percent**.

### *DIABETES*

In California, there are an estimated **3,088,741 people living with diabetes**.

**9.7% of California residents live with diabetes.**

Source: Committee tabulations of Center for Disease Control and Prevention, 2017 Diagnosed Diabetes Statistics, and 2018 pharmaceutical price data from recognized price sources.

### *INSULIN COSTS*

For the most commonly used insulin medications, California residents spend anywhere from **\$1,200 to \$20,000 annually**.

H.R. 3 can lower the average total cost of the insulin NovoLOG Flexpen by 76% from about **\$19,800 to \$4,800 per year**.

Under H.R. 3, California residents could spend **3.5 times less on insulin**.

Under H.R. 3, some commonly used insulins can cost as little as **\$400 per year**.

Source: Committee tabulations of 2018 pharmaceutical price data from recognized price sources.